Projects per year
Personal profile
Education/Academic qualification
Master
Doctor
Fingerprint
Dive into the research topics where Gabriela Torrea is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 3 Finished
-
CUBA - 2018 - FA4: To strengthen Institute of Tropical Medicine Pedro Kouri (IPK, Cuba) and National Institute of Hygiene, Epidemiology and Microbiology (INHEM, Cuba) towards accomplishment of their academic mission through capacity building and scientific co-operation.
Boelaert, M., Vanlerberghe, V., Battaglioli, T. C. E., De Baetselier, I., de Jong, B., Torrea, G., Ariën, K., Heyndrickx, L. & Everaert, R.
1/01/18 → 31/12/18
Project: Development project
-
Studies on multidrug resistance tuberculosis in Rwanda: Turning off the tap
Ngabonziza, S. J., de Jong, B., Torrea, G., Rigouts, L., Mazarati, J., Affolabi, D. & Decroo, T.
1/09/17 → 23/06/21
Project: PhD-project
-
Molecular Characterization of Mycobacterial Isolates Causing Tuberculosis in Humans and Animals in Northwest Ethiopia
Kitata, M. E., de Jong, B., Diro, E., Rigouts, L., Torrea, G. & Gehre, F.
1/02/16 → 16/06/22
Project: PhD-project
Research output
-
Acquired rifampicin resistance during first TB treatment: magnitude, relative importance, risk factors and keys to control in low-income settings
Van Deun, A., Bola, V., Lebeke, R., Kaswa, M., Hossain, M. A., Gumusboga, M., Torrea, G., De Jong, B. C., Rigouts, L. & Decroo, T., 2022, In : JAC-Antimicrobial Resistance. 4, 2, 9 p., dlac037.Research output: Contribution to journal › A1: Web of Science-article
-
Keeping up with the guidelines: design changes to the STREAM stage 2 randomised controlled non-inferiority trial for rifampicin-resistant tuberculosis
STREAM Trial Team, 2022, In : Trials. 23, 1, 7 p., 474.Research output: Contribution to journal › A1: Web of Science-article
-
Multidrug-resistant tuberculosis control in Rwanda overcomes a successful clone that causes most disease over a quarter century
Ngabonziza, J. C. S., Rigouts, L., Torrea, G., Decroo, T., Kamanzi, E., Lempens, P., Rucogoza, A., Habimana, Y. M., Laenen, L., Niyigena, B. E., Uwizeye, C., Ushizimpumu, B., Mulders, W., Ivan, E., Tzfadia, O., Muvunyi, C. M., Migambi, P., Andre, E., Mazarati, J. B., Affolabi, D. & 6 others, , 2022, In : Journal of Clinical Tuberculosis and Other Mycobacterial Diseases. 27, 100299.Research output: Contribution to journal › A1: Web of Science-article
-
Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment
Antimycobacterial Susceptibility T, 2022, In : European Respiratory Journal. 59, 4, 11 p., 2200166.Research output: Contribution to journal › A1: Web of Science-article
-
Effectiveness of GenoType MTBDRsl in excluding TB drug resistance in a clinical trial
STREAM Collaborators, 2021, In : International Journal of Tuberculosis and Lung Disease. 25, 10, p. 839-845 7 p.Research output: Contribution to journal › A1: Web of Science-article